PMID- 17204999
OWN - NLM
STAT- MEDLINE
DCOM- 20070319
LR  - 20171116
IS  - 0090-3493 (Print)
IS  - 0090-3493 (Linking)
VI  - 35
IP  - 2
DP  - 2007 Feb
TI  - Reduced monocyte CD86 expression in postinflammatory immunodeficiency.
PG  - 458-67
AB  - OBJECTIVE: Major surgery, polytrauma, stroke, and pancreatitis frequently lead to 
      a compensatory anti-inflammatory response syndrome that often predisposes 
      patients to lethal infections. This temporary postinflammatory immunodeficiency 
      is characterized by altered function of blood monocytes. These cells show 
      strongly reduced inflammatory and antigen-presentation capacity. Diminished 
      monocyte expression of the major histocompatibility complex class II molecule 
      human leukocyte antigen (HLA)-DR is a well-established diagnostic marker of this 
      immunodeficiency. To further characterize the monocytic cells in this clinical 
      state, we analyzed their expression of CD86, the most important co-stimulatory 
      molecule. DESIGN: Analysis of blood samples that entered the clinical immunologic 
      diagnostics and of cells from an in vitro model of postinflammatory 
      immunodeficiency. SETTING: University laboratory. SUBJECTS: Healthy donors and 
      intensive care unit (ICU) patients at the university hospital. INTERVENTIONS: 
      None. MEASUREMENTS AND MAIN RESULTS: The expression of HLA-DR on monocytes and of 
      CD86 and CD80 on monocytes and B cells was analyzed by flow cytometry. Messenger 
      RNA expression of CD86 was analyzed in isolated monocytes by real-time polymerase 
      chain reaction on reverse transcribed. The normal range of monocyte CD86 
      expression in healthy subjects was established to be from 2128 to 5102 surface 
      molecules per cell and was independent of age, gender, and leukocyte and monocyte 
      count. The CD86 expression on monocytes in ICU patients correlated with HLA-DR 
      expression. Approximately 40% of the ICU patients with long-term reduced monocyte 
      HLA-DR expression had a long-term reduction of CD86 expression. Patients in whom 
      the expression of both molecules was diminished had an unfavorable prognosis. The 
      diminished number of CD86 surface molecules on monocytes was associated with 
      reduced CD86 messenger RNA levels in these cells. The expression of CD86 in B 
      cells was not diminished in immunodeficient patients. The expression of CD80 in 
      both monocytes and B-cells was minimal in healthy donors and not clearly changed 
      in patients. CONCLUSIONS: The monocyte CD86 expression may be a helpful 
      diagnostic variable in ICU patients.
FAU - Wolk, Kerstin
AU  - Wolk K
AD  - Institute of Medical Immunology and Department of General, Visceral, Vascular, 
      Thoracic Surgery, University Hospital Charite, Berlin, Germany.
FAU - Hoflich, Conny
AU  - Hoflich C
FAU - Zuckermann-Becker, Heidrun
AU  - Zuckermann-Becker H
FAU - Docke, Wolf-Dietrich
AU  - Docke WD
FAU - Volk, Hans-Dieter
AU  - Volk HD
FAU - Sabat, Robert
AU  - Sabat R
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Crit Care Med
JT  - Critical care medicine
JID - 0355501
RN  - 0 (B7-2 Antigen)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - B7-2 Antigen/*biosynthesis/*blood
MH  - Female
MH  - Humans
MH  - Immunologic Deficiency Syndromes/*blood/*immunology
MH  - Inflammation/*blood/*immunology
MH  - Male
MH  - Middle Aged
MH  - Monocytes/*immunology
EDAT- 2007/01/06 09:00
MHDA- 2007/03/21 09:00
CRDT- 2007/01/06 09:00
PHST- 2007/01/06 09:00 [pubmed]
PHST- 2007/03/21 09:00 [medline]
PHST- 2007/01/06 09:00 [entrez]
AID - 10.1097/01.CCM.0000254724.54515.2F [doi]
PST - ppublish
SO  - Crit Care Med. 2007 Feb;35(2):458-67. doi: 10.1097/01.CCM.0000254724.54515.2F.